# Verixa Seed Fundraising Strategy — VC Approach & Execution
**Prepared:** 2026-06-12 · **Skills applied:** investment-banking-capital-advisor + aeonn-ark-founder-advisor
**Evidence base:** Verixa_Investor_Deck_v7.1.pptx (May 2026) · verixa-investor-memo-v2.md (May 2026)

---

## 1. Transaction Scope

| Field | Detail | Evidence status |
|---|---|---|
| Transaction type | Seed equity raise, $2M at $8M pre-money ($10M post, ~20% dilution) | [Fact — deck slide 17] |
| Instrument | Priced vs SAFE/CCPS not stated | Unknown — evidence required |
| Jurisdiction | 🌐 Cross-border: Navira Regulatory Technologies, Inc. (US) + Navira Regulatory Technologies Pvt Ltd (India) | [Fact — deck slide 1] |
| Objective | 18-month runway to validation milestones → Series A readiness | [Fact — slide 17] |
| Stage | Architecture-complete, pre-validation, pre-revenue | [Fact — memo] |
| Cap table | Not supplied | Unknown — evidence required |
| Cash on hand / burn / runway pressure | Not supplied | Unknown — evidence required |
| Legal counsel / securities-law review status | Not supplied | Unknown — evidence required |

**Naming inconsistency flagged:** memo says "Navira Technologies, Inc"; deck says "Navira Regulatory Technologies, Inc." Confirm the registered US entity name before any investor document goes out.

---

## 2. Critical Pre-Outreach Dependency: Entity Structure

The dual-entity US + India footprint is a GTM asset but a fundraising hazard if unresolved. Investors fund **one cap table**.

| Question | Why it gates outreach |
|---|---|
| Which entity issues the equity? | US VCs (Lightspeed, Bessemer, YC) typically require a US (Delaware) parent. India funds (Blume, HealthQuad) can invest in either but priced expectations differ. |
| Is India Pvt Ltd a wholly-owned subsidiary of the US Inc? | If not, a flip/subsidiary restructuring may be needed — FEMA/RBI, ODI/FDI route, and transfer-pricing consequences. |
| Founder shareholding & residency | Determines FEMA treatment and US tax exposure. |

`Legal dependency — qualified counsel required` (cross-border corporate + securities). US side: Reg D private placement discipline — no general solicitation; the deck must remain non-public.
`Tax dependency — route to principal-crossborder-tax-legal-advisor skill` before structure lock.

**Do not start partner meetings until the answer to "which entity, what instrument" is one sentence long.**

---

## 3. Valuation Reality Check (Devil's Advocate)

- [Fact] $8M pre, pre-revenue, pre-LOI, solo founder (confirmed by founder 2026-06-12; memo label corrected from "Co-Founder" to "Founder & CEO" — deck v7.1 was already correct).
- **Solo-founder objection — prepare the counter, don't hide it:** (1) domain depth is the moat — 20+ yrs, 16+ in QA/Reg, this is a founder-market-fit story; (2) the seed plan already converts solo risk into a hiring plan — VP Engineering, Head of Validation, Head of GTM India are named first hires funded by the round; (3) the regulatory advisory board (ex-FDA/EMA/CDSCO, Q1 2027) substitutes for missing senior bench at this stage. Consider naming the VP Engineering candidate (or a committed fractional CTO) before partner meetings — that single move neutralizes most of the objection. India funds in particular underwrite solo technical-domain founders less often; expect this hardest in Lane B conversations.
- [Assumed] $8M pre is at the top of the range for a pre-revenue India-anchored seed; more defensible with US investors given founder domain depth (20+ yrs, Genentech/BMS/Arcellx/Alumis) and category momentum (Ketryx $39M B, Dot Compliance, Aizon).
- Comparable seed-stage valuations for Ketryx/Entvin: `Current source required` — do not cite without verification.
- [Assumed] Each signed design-partner LOI materially de-risks the price. Raising at $8M pre **after** 2–4 LOIs is a normal conversation; raising before any LOI invites either price compression or pass.

---

## 4. Strategic Options

| Option | Capital path | Time to value | What must be true | Reversibility |
|---|---|---|---|---|
| **A. LOI-first sequenced raise** — spend 6–10 weeks converting founder network (Alumis/Arcellx/BMS/Genentech) + 14 India First Wave accounts into 2–4 LOIs, then run a tight 8-week process | $2M institutional seed | First close Q4 2026 | Network converts to LOIs; cash supports the delay | High |
| **B. Immediate broad outreach** — start partner meetings now on architecture story alone | $2M | Q3–Q4 2026 | Investors buy pre-LOI at $8M pre | Medium — early passes burn the best names |
| **C. YC + angel bridge** — apply YC (they funded Entvin, Ritivel in this exact lane); raise $300–500K bridge from pharma-quality operator angels meanwhile | $0.3–0.5M then $2M+ | Bridge ~Q3 2026; seed H1 2027 | YC acceptance or angel conviction | High |
| **D. India-led seed** — Blume/HealthQuad/Chiratae lead at India-market terms; US funds join later | $2M (possibly re-priced) | Q4 2026 | India entity can take the round cleanly; valuation flexibility | Medium |
| **E. Pharma CVC / strategic** | Varies | Slow (6–12 mo) | Strategic alignment without lock-in | Low — signaling risk at seed |

## 5. ICET-R (directional, [Assumed])

| Option | Impact | Confidence | Effort (↓) | Time-to-Value | Risk (↓) | Read |
|---|---|---|---|---|---|---|
| A | 9 | 7 | 6 | 7 | 4 | **Primary** |
| B | 7 | 4 | 7 | 8 | 7 | Weak — burns optionality |
| C | 7 | 6 | 4 | 6 | 3 | **Fallback / parallel** |
| D | 7 | 6 | 5 | 7 | 5 | Lane within A |
| E | 5 | 3 | 8 | 3 | 7 | Defer to Series A |

---

## 6. Recommendation

**Primary: Option A — LOI-first, dual-lane, with C running in parallel.**

The memo itself states the mitigation for "no pilots yet" is *"prioritize design-partner LOIs before broad fundraising narrative."* Follow your own doctrine. Concretely:

1. **Weeks 1–2:** resolve entity/instrument with counsel; fix the co-founder label and entity-name inconsistency; build the data room (URS, scope-lock matrix draft, competitive landscape xlsx, IP narrative — most artifacts already exist in the workspace).
2. **Weeks 1–8:** LOI sprint. Lane A — 10–15 warm conversations from the clinical-quality network. Lane B — the 14 First Wave India CDMO accounts. Target: 2 LOIs per lane. Submit YC application in parallel.
3. **Weeks 6–8:** soft-circle "first-call" investors for advice-not-money meetings: Lightspeed (US+India), NewVale, Blume, HealthQuad, Vertex. Use these to test the narrative without asking.
4. **Weeks 9–16:** formal process. Batch all partner meetings into a 2–3 week window to create parallel momentum. Lead candidates: Lightspeed or Blume/HealthQuad (lead), NewVale/Vertex/angels (fill). Hold Transformation Capital, Bessemer, OrbiMed, a16z as Series A relationship-builds — meet them now, raise from them later.
5. **Anchor the urgency:** FDA Warning Letter 722591 (Apr 2026) + EU AI Act Aug 2, 2026 application date is a live, dated "why now" — the process should be timed so partner meetings happen while that date is in front of investors.

**Fallback:** if <2 LOIs by end Q3 2026 → pivot to Option C (YC + $300–500K operator-angel bridge), and revisit the $8M pre.

### Why others lose
- B converts founder bandwidth into early passes at the highest-value firms.
- D alone under-uses the founder's US network — but it is the strongest lane *inside* A.
- E mis-times strategic capital; their diligence cycle exceeds your runway logic.

### Kill criteria / reversal triggers
- No LOI from 25+ qualified conversations by 30 Sep 2026 → narrative or ICP problem; stop raising, fix product evidence.
- Partner-meeting-to-second-meeting conversion <20% → reposition before continuing.
- Counsel finds the dual-entity structure needs a flip → pause outreach until done; raising into a broken structure is worse than delay.

---

## 6A. Co-Founder Search Workstream (added 2026-06-12)

**Founder decision [Fact]:** Vimal repositions as Founder & CPO; search targets a **CEO/commercial co-founder**; geography flexible (US or India — dual entity supports both).

**Profile spec:**
- Operated and scaled B2B enterprise SaaS (ideally regulated/life-sciences: ex-Veeva, MasterControl, Dot Compliance, Qualio commercial leadership — or a second-time founder with an exit in pharma/health SaaS)
- Has raised institutional capital as founder/CEO (fundraising as byproduct of operating record, not the headline skill)
- Enterprise GTM + early-team hiring capability; comfortable with India + US dual-lane motion

**Economics & terms:** 20–40% equity, 4-year vesting / 1-year cliff, defined decision-rights split (CEO: fundraise, GTM, ops · CPO: product, regulatory architecture, validation roadmap). Mandatory 4–8 week working trial before signing. `Legal dependency — qualified counsel required` for founder agreement + revised cap table.

**Channels:** YC Co-Founder Matching (pairs with YC application) · Entrepreneur First Bangalore · Antler India · South Park Commons · EIR intros from Blume / Lightspeed / HealthQuad (doubles as investor warming) · direct sourcing of ex-Veeva/Dot Compliance commercial leaders.

**Sequencing rules (critical):**
1. Sign the CEO co-founder **before** the priced seed closes if at all possible — clean equity at formation pricing; post-close it requires investor consent and dilution negotiation.
2. During investor meetings, do not present as "searching for a CEO" — it reads as the founder stepping back. Position: "I lead the company and the raise; I'm recruiting a commercial co-founder to scale GTM." If signed before process start, the solo-founder objection disappears entirely.
3. Do not gate the LOI sprint on the search — LOIs come from Vimal's own network and are CPO-native work.
4. Kill criterion: no signed co-founder by first close → proceed solo with named senior bench; do not take a marginal co-founder under raise pressure. A wrong co-founder is the most expensive mistake available at this stage.

**CEO pathway — LOCKED (founder decision 2026-06-12):**

| Stage | Leadership model | Rationale |
|---|---|---|
| Now → seed close | **Vimal = Founder & CEO** (CPO repositioning deferred until co-founder signs). Co-founder search runs in parallel; sign before close if a great candidate lands. | Seed-stage CEO work = fundraising + first sales to founder's own network — only Vimal can credibly do it. Hired CEO at pre-revenue = negative selection + VC red flag + unaffordable (retained search 25–33% of first-year comp + $250–400K salary vs 10% ops budget). |
| Seed → Series A | If no co-founder: hire **VP Sales / CRO** (employee economics) to carry commercial load; Vimal retains CEO title. | Strong commercial VPs are findable at this stage; preserves founder-led narrative for Series A. |
| Series A/B | **Executive-search CEO becomes viable.** Vimal formally steps to CPO/Chairman; board shares cost and selection. | Search firms do their best work for funded, revenue-stage companies; hiring from strength, not need. |

Executive search for CEO at seed stage: **rejected** — cash-infeasible, negative-selection risk, and signals founder retreat to investors.

## 7. Investor Pipeline (from deck slide 18, validated + re-prioritized 2026-06-12)

| Priority | Firm | Rationale | Action |
|---|---|---|---|
| 1 | Lightspeed | Led Ketryx A; large India practice — matches dual-entity | Warm intro; seed-stage fit |
| 1 | Blume Ventures | Fund V $175M; deeptech/healthtech pre-seed onward | India lead candidate |
| 1 | HealthQuad | Fund III deploying; healthcare specialist | India lead candidate |
| 1 | NewVale Capital | Led Aizon C; pharma-manufacturing specialist | Direct thesis fit |
| 1 | Y Combinator | Funded Entvin, Ritivel (pharma reg AI) | Apply now |
| 2 | Vertex Ventures | Dot Compliance backer; India/SEA fund | Seed participant |
| 2 | Chiratae, Stellaris, Kalaari, Endiya | India seed lane depth | Second-call tier |
| 2 | Ubiquity Ventures, MIT E14 | Ketryx seed-stage backers | Seed participants |
| 3 | Transformation Capital, Bessemer, OrbiMed, General Catalyst, a16z Bio+Health | Growth/A-stage; category conviction | Relationship-build for Series A |
| 4 | **Angels & syndicates** — curated domain operators first (pharma CDMO promoters, ex-Veeva/IQVIA India execs, retired plant quality heads); networks second: BioAngels (healthtech-specific), IAN, 1Crowd; Native Angels Network [Unverified — confirm active + terms] | Fill capital (10–20% of round max, post-lead) **or** the Gate-2 fallback bridge ($300–500K) | Engage after lead secured, or at bridge trigger |

**Angel discipline rules (locked 2026-06-12):**
1. Single SPV/AIF line on the cap table — never 15–30 direct individual shareholders (Series A diligence problem).
2. Never pay to pitch — listing/success fees charged to founders = negative selection; walk.
3. Curated domain angels > generic networks — a CDMO promoter's ₹50L cheque carries Lane B customer intros; source via founder's own network first.
4. Signaling: don't lead the institutional narrative with angel-network paper; operator angels strengthen it, generic networks don't.

---

## 8. Required Work Products (before first partner meeting)

1. Cap table + ESOP pool plan — `Unknown — evidence required`
2. Instrument decision memo (SAFE vs priced CCPS vs priced Delaware) — counsel
3. Cross-border structure opinion (FEMA/ODI/flip) — counsel + tax
4. 18-month operating budget tying to the 45/20/20/5/10 use-of-funds split
5. Phase 1 scope-lock matrix (already a Q3 2026 milestone — pull it forward; it is also an investor-diligence document)
6. Data room index + LOI template
7. Investor CRM tracker (can be built from this pipeline)

## 9. PROJECT STATE (fundraise)

- **A. Entities:** Navira Reg Tech Inc (US) + Pvt Ltd (India). Ownership/structure between them: [Unknown]
- **B. Cash/burn:** [Unknown — required to time the process]
- **C. Pipeline:** 14 First Wave India accounts [Fact — deck]; US network targets unquantified
- **D. Top priorities:** structure lock → LOI sprint + CEO co-founder search (parallel) → YC app → batched process Q4 2026
- **D1. Founder role:** Vimal = Founder & CPO [Fact, 2026-06-12]; CEO/commercial co-founder search open, geography flexible
- **E. Open risks:** solo-founder objection (mitigation: named first hires + advisory board + consider committed VP Eng/fractional CTO pre-process); $8M pre pre-LOI; Annex 22 still draft; dual-entity complexity
- **F. Decision log:** 2026-06-12 — strategy drafted; LOI-first sequencing recommended (this doc). 2026-06-12 — founder confirmed solo founder; memo "Co-Founder" label corrected. 2026-06-12 — CEO pathway locked: co-founder search now → CRO at seed if unfilled → exec-search CEO at Series A/B; exec search at seed rejected. 2026-06-12 — EXTERNAL REVIEW ADOPTED (tracker v2): five-gate system (G0 Claim Safety → G1 Structure/IP → G2 Qualified Evidence → G3 Diligence Pack → G4 Close); EU AI Act "Aug 2, 2026 high-risk" anchor REMOVED (verified: May 7, 2026 omnibus defers Annex III high-risk to Dec 2, 2027, Annex I embedded to Aug 2, 2028) — urgency re-anchored on FDA WL 722591 + CSA + FDA–EMA GAIP + Annex 22 draft; GATE 2 redefined to QUALIFIED LOIs (named sponsor, use case, evaluation window, buyer role, data scope, security constraints, success criteria, payment status, investor-disclosure permission — vague LOIs do not count); Tier-1 meetings relationship-only until G2 passes; security/procurement lane added (pre-LOI buyer diligence pack within 7 days; SOC 2/ISO path); hiring narrative reconciliation required (budget vs deck/3-yr plan — ONE story) before partner meetings; related-party Sense7ai engineering arrangement disclosed at G1; "validation package" and "inspection outcome" language softened to non-overclaiming wording. Founder's standing answer to evidence-vs-investor-interest: EVIDENCE FIRST — no qualified LOIs, no priced process (G2 fallback = bridge).

## 10. Confidence

**62%.** Raises: cap table + cash position supplied; structure opinion obtained; first LOI signed. Lowers: runway pressure forcing Option B; structure requiring a flip; co-founder question unresolved.

---

*Strategic and analytical guidance only — not investment, legal, tax, or placement advice. Securities offering execution requires qualified counsel; no solicitation activity is performed by this analysis.*